Merck Stock Not Likely To Be Saved By Dividends

Summary:

• Merck & Co., Inc. has increased reliance on Keytruda and Gardasil.
• Merck became a Seeking Alpha Quant system Strong Buy on July 11 for no clear reason.
• Clinical catalysts have so far not moved Merck stock upward.

Our previous coverage on Merck & Co., Inc. (NYSE:MRK), a large (~$272 billion market cap) biopharmaceutical, rated it a Hold. This was due to its top two products Keytruda and Gardasil facing a U.S. patent cliff in 2028, sparse insurance coverage for Reblozyl, and lack of sales support from the company’s newer non-vaccine drugs (Prevymis, Verquvo, Zerbaxa, and WELIREG). Accordingly, share prices have been flat since that prior article’s publication, but that’s not a positive. The reference SPDR® S&P 500 ETF Trust (SPY) has outperformed Merck by close to 14% during that period.

In the first quarter, things have gotten worse. Merck became even more reliant on Keytruda and Gardasil, which combined to generate $7.77 billion (an impressive +24% year-over-year) but also comprised 61% of pharmaceutical sales, compared to 57% in Q4 2022 (Table 1). Merck inexplicably became a Strong Buy according to Seeking Alpha’s Quant system on July 11, despite no change in any component grade from the day before, no news, and no SEC filings, prompting a similar Strong Buy from another SA analyst. Unfortunately, given how the market has greeted the company’s clinical/regulatory catalyst events so far, there seem to be few if any real sources of relief for Longs for the rest of the year.

Table 1. Merck Quarterly Product Sales

	2022				2023
	1Q	2Q	3Q	4Q	1Q
TOTAL SALES	$ 15,901	$ 14,593	$ 14,959	$ 13,830	$14,487
PHARMACEUTICAL	14,107	12,756	12,963	12,180	12,721
Oncology
Keytruda	4,809	5,252	5,426	5,450	5,795
Alliance Revenue – Lynparza	266	275	284	292	275
Alliance Revenue – Lenvima	227	231	202	216	232
Alliance Revenue – Reblozyl	52	33	39	41	43
Welireg	18	27	38	40	42
Vaccines
Gardasil / Gardasil 9	1,460	1,674	2,294	1,470	1,972
ProQuad / M-M-R II / Varivax	470	578	668	526	528
RotaTeq	216	173	256	139	297
Vaxneuvance	5	12	16	138	106
Pneumovax 23	173	153	131	145	96
Vaqta	36	35	64	39	40
Hospital Acute Care
Bridion	395	426	423	441	487
Prevymis	94	103	114	118	129
Primaxin	58	64	63	54	80
Dificid	52	66	77	67	65
Noxafil	57	60	62	58	60
Zerbaxa	30	46	43	49	50
Cardiovascular
Alliance Revenue – Adempas/Verquvo	72	98	88	82	99
Adempas (Merck territories)	61	63	57	57	59
Virology
Lagevrio	3,247	1,177	436	825	392
Isentress / Isentress HD	158	147	161	167	123
Neuroscience
Belsomra	69	69	62	59	56
Immunology
Simponi	186	181	173	166	180
Remicade	61	53	49	44	51
Diabetes
Januvia	779	756	717	561	551
Janumet	454	476	417	353	329
Other Pharmaceutical	602	528	603	583	584
ANIMAL HEALTH	1,482	1,467	1,371	1,230	1,491
Livestock	832	826	829	814	849
Companion Animals	650	641	542	416	642
Other Revenues	312	370	625	420	275

Click to enlarge

Excluding COVID-19 antiviral Lagevrio, the duo led pharma sales to $12.7 billion (+13.5% YOY) and a revenue beat. However, Reblozyl regressed by 18% and none of the other newer products contribute at least $130 million (1% of sales). Keytruda and Gardasil just don’t seem to excite the masses.

There has, at least, been some recent progress in the pipeline:

On March 1, Keytruda delivered positive top line results from the Phase 3 KEYNOTE-671 trial as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB non-small cell lung cancer (NSCLC). The FDA review of Merck’s supplemental Biologics License Application (“sBLA”‘) based on these data and has set a Prescription Drug User Fee Act (PDUFA), or target action date of Oct. 16, 2023.

On April 3, the FDA granted accelerated approval of Keytruda in combination with Astellas Pharma’s (OTCPK:ALPMY) Padcev for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on data from the KEYNOTE-869 trial.

In April, the FDA accepted Merck’s sBLA based on the pivotal Phase 3 KEYNOTE-859 trial, where KEYTRUDA in combination with chemotherapy significantly improved overall survival (“OS”‘) versus chemotherapy alone as first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The Agency set a PDUFA date of Dec. 16, 2023.

On June 1, the FDA approved LYNPARZA plus abiraterone and prednisone or prednisolone (abi/pred) as a first-line treatment of adult patients with BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Hopefully, this will bolster the drug’s 3% Q1 YOY performance next quarter.

On June 6, the FDA approved a new prophylactic indication for antiviral agent PREVYMIS in adult kidney transplant recipients at high risk for cytomegalovirus (“CMV”) disease. A study demonstrated that PREVYMIS was non-inferior to valganciclovir, the current standard of care (“SOC”), at preventing incidence of CMV. Insurance will require the cheaper generic valganciclovir treatment first, but PREVYMIS will see use as a second option, and will finally contribute more than 1% to Merck’s sales.

On June 8, the FDA accepted the sBLA for Keytruda as a treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (“BTC”), based on data from the KEYNOTE-966 trial, in which Keytruda plus chemotherapy demonstrated a statistically significant improvement in OS compared to chemotherapy alone. The Agency set a PDUFA date of February 7, 2024.

While the list of developments is long, none of these are likely to improve total sales until at least next year, when approved KEYTRUDA label expansions are adopted into clinical practice. None have impacted share price. Merck retains an A+ Quant Profitability grade due to high margins, but the B for Momentum is a relative mirage compared to the broad market. Big Pharma stocks promoted for their dividends have all underperformed among my personal recommendations since last year (Figure 1). Why hang on for so-so yields when the underlying stock is stagnant or depreciates at a larger clip? Merck has nothing special that sets it apart to gain a Buy rating. To conclude, the lack of positive MRK price action, and the apparent continuing movement by the market away from dividend-carrying large-caps as suitable defensive healthcare stocks in a bear market, keep Merck a Hold.

Figure 1. Performance of CSI’s Buys and Strong Buys from September 2022 compared to SPY

Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

---

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

---